Unicycive Therapeutics’ (UNCY) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $3.00 target price on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $5.50.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $0.66 on Wednesday. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.82. The stock has a market cap of $68.96 million, a PE ratio of -0.68 and a beta of 2.30. The stock has a fifty day moving average of $0.66 and a 200-day moving average of $0.49.

Institutional Trading of Unicycive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Walleye Capital LLC purchased a new stake in Unicycive Therapeutics during the third quarter valued at about $2,040,000. Great Point Partners LLC purchased a new position in shares of Unicycive Therapeutics during the 3rd quarter valued at about $3,491,000. Acuta Capital Partners LLC purchased a new position in shares of Unicycive Therapeutics during the 3rd quarter valued at about $807,000. Virtu Financial LLC lifted its position in Unicycive Therapeutics by 566.8% in the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after buying an additional 62,881 shares during the last quarter. Finally, Bleakley Financial Group LLC purchased a new stake in Unicycive Therapeutics in the third quarter worth approximately $33,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.